Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study

•Fondaparinux was granted a European market authorization for SVT treatment.•In France, fondaparinux is currently the first drug prescribed in SVT by vascular physicians.•SVT drug prescriptions, dosage and duration continue to vary widely.•The study supports the extrapolability of CALISTO results in...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2017-09, Vol.157, p.117-119
Main Authors: Blin, P., Sevestre, M.A., Pouchain, D., Gillet, J.L.
Format: Article
Language:English
Subjects:
Aged
Anticoagulants
Anticoagulants - therapeutic use
Cohort Studies
Cohort study
Deep vein thrombosis
Female
Humans
Lower Extremity - blood supply
Male
Pharmacoepidemiology
Venous thromboembolism
Venous Thrombosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Fondaparinux was granted a European market authorization for SVT treatment.•In France, fondaparinux is currently the first drug prescribed in SVT by vascular physicians.•SVT drug prescriptions, dosage and duration continue to vary widely.•The study supports the extrapolability of CALISTO results in every-day practice.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2017.07.009